Spotlight Innovation Inc. announced that it has made a strategic investment in Solx, Inc. Principally backed by MVM Life Science Partners, Solx develops innovative surgical technologies that treat glaucoma and preserve vision. Solx's lead product is the SOLX Gold Shunt™, implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. Approved for use in Canada and Europe, the SOLX Gold Shunt has been tested in a multi-center clinical trial, is investigational and awaiting FDA approval in the U.S.